Preventing the spread of pathogens within livestock, and from livestock to

humans is essential for ensuring both animal and human welfare. QIAGEN is
committed to providing high-quality, easy-to-use, and sensitive molecular
solutions

to

enable

veterinary

pathogen

detection.

Our objective is to partner with researchers and provide high-quality molecular

solutions for all components of the workflow, from sample isolation to analyte
detection and analysis.
QIAGEN provides extensive sample extraction and assay solutions, assay setup
instruments, and detection platforms. QIAGENs portfolio for molecular
veterinary testing and animal pathogen research includes both ELISA- and
PCR-based molecular solutions. ELISA allows the detection of specific
antibodies generated in response to infections. PCR assays detect DNA or RNA
of infecting pathogens.
Explore your area of interest and QIAGEN's workflow solutions.
QIAGEN sample and assay technologies are used in labs around the world
where reliable, standardized solutions are needed for automated or manual
purification and analysis of DNA, RNA, and proteins.
Qiagen
From Wikipedia, the free encyclopedia

[hide]This article has multiple issues. Please help improve it or di

This article appears to be written like an advertisement. (Novemb
This article needs additional citations for verification. (May 2011)
Qiagen N.V.

Type

Naamloze vennootschap

Traded NASDAQ: QGEN, FWB: QIA

as
Industr Biotechnology
y
Founde 1984
d
Headqu Venlo, Netherlands (corporate);Hild
arters

en, Germany (operational)

Key

Peer Schatz (CEO and chairman of

people

the

executive

board),

Riesner (Chairman of
thesupervisory board)
Revenu US $1.169 billion (2011)[1]
e

Detlev

Operati US $319.6.5 million (2011 adjusted)

ng

[1]

income
Profit

US $234.4 million (2011 adjusted)[1]

Total

US

assets

September 2012)[2]

Total

US

equity

September 2012)[2]

$3.956

$2.712

Employ about
ees

billion (end

billion (end

4,000 (end

of

of

of

September

2012)[3]

Website www.qiagen.com
Qiagen is a provider of sample and assay technologies for molecular
diagnostics,

applied

testing,

academic

and

pharmaceutical

research.

Consolidated under the Dutch holding Qiagen N.V., the company operates more
than 35 offices in over 20 countries. Qiagens shares are listed at the
technology-focused U.S. stock exchange Nasdaq (using ticker QGEN) and at
the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). Peer M.
Schatz is the companys Chief Executive Officer. The main operative
headquarters are located in Hilden, Germany (nearDsseldorf).
Contents
[hide]

1 Products

2 Application areas

3 History

4 Management

5 Structure of the company

6 References

7 External links
Products[edit]
For Qiagen columns, see column-based nucleic acid purification.
QIAGEN is a worldwide provider of molecular sample and assay technologies.
Sample technologies are used to collect samples of tissue, fluids, etc. and
stabilize,

extract

and

purify

various

molecules

of

interest

such

as DNA, RNA or proteins from other cellular components. Assay technologies

are then used to amplify (multiply) and enrich this small amount of isolated
material to make it visible, readable and ready for interpretation. The separation
and purification of genetic information is a basic precondition for further
application or analysis.

Qiagen provides molecular technologies offered as kits with open or specific

target analytes. According to Qiagen, the companys current portfolio covers
more than 500 products and more than 2,400 patents and licenses.[4]
Application areas[edit]
Until the mid-2000s, the company was mainly a provider of sample
technologies for the academic research market. Today, Qiagens product
portfolio includes sample and assay technologies along with specific automation
solutions in the following 4 markets:
Molecular Diagnostics (MDx): Molecular diagnostics detect the nucleic acids
(DNA and RNA) of target diseases or pathogens in samples such as blood or
tissue. These procedures can help to detect viruses and bacteria more rapidly
and with greater sensitivity and specificity than other methods such as bacterial
culture or immunodiagnostics.[5] Molecular diagnostics are also used to analyze
individual patient's genomic information to further classify certain diseases and
to determine the most appropriate treatment. Qiagens portfolio in molecular
diagnostics covers various applications which the company divides into four
main segments:[6]
Prevention: The screening of asymptomatic patients such as HPV testing for
detection of high-risk types of the human papillomavirus (HPV), the primary
cause of cervical cancer, or for latent tuberculosis.

 Profiling: The testing of symptomatic patients who are at risk of carrying an

infectious disease such as Hepatitis, HIV, TB etc. Qiagen manufactures more
than 120 molecular diagnostic tests for use in profiling.
Personalized Healthcare: The optimization of treatments for symptomatic, prediagnosed patients. Potential applications of these tests primarily focus on the
treatment of various cancers.
Point of Need: Low-throughput molecular testing in settings that lack a
laboratory infrastructure or require fast turnaround times.
Applied

Testing

(AT): Applied

Testing

is

the

use

of

molecular

biology/diagnostics in practical, non-clinical applications such as veterinary

medicine, forensics, food-quality monitoring and protection against biological
hazards. Qiagen's portfolio includes:
Food safety: tests for pathogens (such as salmonella, legionella and listeria),
allergens, genetically modified organisms as well as food origin and quality.
Veterinary medicine: tests for pathogens (such as bird flu, for which Qiagen
was the first company to offer an approved test) as well as pandemic prevention
and monitoring.
Forensics: tests used to identify victims, prosecute criminals and determine
paternity or lineage.

Academic Research: The life science research market encompasses all

disciplines focusing on living organisms such as humans, animals, plants or
bacteria (e.g., biochemistry, biomedicine or genetic engineering). Much of the
research is done on a molecular level targeting DNA, RNA and proteins and
helps scientists to comprehend basic processes in cells and organisms.
Qiagen introduced the first kit for purification of plasmids small ring-shaped
DNA molecules in bacterial cells in 1986, cutting the preparation time for
plasmids from between two and three days down to two hours. The company
has a global market share exceeding 70% for certain sample preparation
technologies.
Pharmaceutical

Industry: Multinational

pharmaceutical

companies

use

molecular sample and assay technologies in all phases of the drug development
process, from the fundamental pharmaceutical research stage, through
preclinical and clinical studies, to the commercialization and application of new
products.
Qiagen technologies can be used to identify genes that participate in the
emergence of diseases, carry out studies on the functions and interactions
between genes (or proteins) in entire biological pathways, identify and validate
potential biomarkers and identify and evaluate therapeutic target molecules and
suitable active agent candidates. Qiagen's products can also be used in the
execution of the clinical studies.

History[edit]
1984 - Qiagen is established on November 29 by a team of scientists at
the University of Dsseldorf.
1986 - Qiagen launches its first product, a kit for purification of plasmids
small ring-shaped DNA molecules in bacterial cells cutting the preparation
time for plasmids from between two and three days down to two hours.
1996 - The initial public offering of Qiagen on the technology-oriented Nasdaq
stock exchange (the first German company to do so)
1997 - The initial public offering on the Frankfurt Stock Exchange (Germany).
2006 - Qiagen establishes its Asia regional headquarters in Shanghai.
2007 - Sales reach US$649.8 million and the number of employees surpasses
2,600. Qiagen acquires Digene for US$1.6 billion, making Qiagen an industry
leader in molecular diagnostics (by revenue) and a leader in diagnostics for
disease prevention.
2009 - Qiagen begins building its Personalized Healthcare business through the
acquisition of DxS Ltd (a deal valued at ~US$ 95 million) [7] and SABiosciences
Corp. (a deal valued at ~US$ 9 million). [8] At the end of 2009 Qiagen surpasses
the US$1 billion revenue mark and has over 3,500 employees. Qiagen becomes
one of the first companies to release a clinically verified diagnostic test for the
detection of H1N1, more commonly known as Swine Flu.[9]

2010 - Qiagen acquires ESE GmbH,[10] giving the company access to point of
need testing devices for the application of molecular diagnostic tests without
laboratory infrastructure. Qiagen launches the QIAsymphony AS and
QIAsymphony RGQ platforms, adding to the companys portfolio for
laboratory workflow automation and molecular test full-process automation
respectively.
2011 - Qiagen acquires Ipsogen S.A. for ~US$101,[11] adding to the companys
product and IP portfolio in the blood cancer space and developing its position in
molecular diagnostics for oncology. Qiagen also acquires Cellestis Limited for
~US$ 374 million,[12] giving the company access to QuantiFERON technology
for disease detection and prevention. The company adds two new offices in the
Asia Pacific region in New Delhi, India and Taipei, Taiwan. The company
announces a comprehensive restructuring program to focus on high-growth
areas such as personalized medicine and business in emerging markets. The
program includes workforce reduction and internal restructuring affecting
approximately 10% of the companys 3,900 positions.[13]
Management[edit]
As of January 2013, the company's Executive Committee consisted of the
following members:[14]

Peer M. Schatz (Chief Executive Officer)

Roland Sackers (Chief Financial Officer)

Dr. Dietrich Hauffe (Senior Vice President Life Sciences Business Area)

Douglas Liu (Senior Vice President Global Operations)

Dr. Helge Lubenow (Senior Vice President Molecular Diagnostics

Business Area)

Dr. Ulrich Schriek (Senior Vice President Corporate Business

Development)

Dr. Thomas Schweins (Senior Vice President Human Resources, Strategy

& Marketing Services)

Benedikt von Braunmuehl (Senior Vice President Global Commercial

Operations)

Qiagen N.V. (QIA) Details

QIAGEN N.V., through its subsidiaries, provides sample and assay technologies
worldwide. It offers approximately 500 core consumable products, such as
sample and assay kits, and automated instrumentation systems that empower
customers to transform raw biological samples into molecular information. The
companys consumable products are used for plasmid deoxyribonucleic acid

(DNA) purification, and ribonucleic acid purification and stabilization; genomic

and viral nucleic acid purification; nucleic acid transfection; polymerase chain
reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR
and sequencing; and DNA cloning and protein purification. The company sells
the digene HC2 HPV Test, a signal-amplified test for high-risk strains of the
human papillomavirus. It also offers co-development services for companion
diagnostics, technology licensing and patent sales services, and custom services,
including whole genome amplification, DNA sequencing, and non-cGMP DNA
production on a contract basis. The companys instrumentation systems
automate the use of sample and assay technologies into solutions for a range of
laboratory needs enabling customers to perform nucleic acid sample
preparation, assay setup, target detection, and other laboratory tasks. Its
automated systems include QIAsymphony, a modular system; Rotor-Gene Q, a
rotary real-time PCR cycler system; PyroMark, a high-resolution detection
platform based upon the Pyrosequencing technology; QIAcube, a sample
processing instrument; QIAxcel for nucleic acid separation in low- to highthroughput

laboratories;

and

ESE-Quant

Tube

Scanners,

an

optical

measurement device. The company serves customer classes, including

molecular diagnostics laboratories; applied testing customers in fields, such as
forensics, veterinary diagnostics, and food safety; pharmaceutical research and
development groups, and academic researchers. QIAGEN N.V. was founded in
1986 and is headquartered in Venlo, the Netherlands

(In $ thousands, except per share data)

2011 2010
Net sales 286,032 334,420
Cost of sales 97,008 132,701
Gross profit 189,024 201,719
ended December 31,
QIAGEN N.V.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
Three months
Operating expenses:
Research and development 32,814 34,039
Sales and marketing 82,319 69,852
General and administrative, integration and other 98,592 28,747
Acquisition-related intangible amortization 7,603 5,614

Total operating expenses 221,328 138,252

(Loss) income from operations (19,609) 50,772
Other income (expense):
Interest income 1,189 1,040
Interest expense (5,877) (6,912)
Other income, net 2,244 474
Total other income (expense) (2,444) (5,398)
(Loss) income before provision for income taxes (22,053) 45,374
Provision for income taxes (21,263) 9,084
Net (loss) income (790) 36,290
Net (loss) attributable to non-controlling interest (412) Net (loss) income attributable to the owners of QIAGEN N. V. (378) 36,290
Weighted average number of diluted common shares 236,669 239,393
Diluted net income per common share attributable to the owners of
QIAGEN N. V. $ 0.00 $ 0.15
Diluted net income per common share attributable to the owners of
QIAGEN N. V. (adjusted) $ 0.31 $ 0.26

(In $ thousands, except per share data)

2011 2010
Net sales 1,087,431 1,169,747
Cost of sales 371,869 419,938
Gross profit 715,562 749,809
Operating expenses:
Research and development 130,636 126,040
Sales and marketing 267,484 307,332
General and administrative, integration and other 185,507 110,009
Acquisition-related intangible amortization 26,746 23,492
Total operating expenses 527,025 650,221
Income from operations 188,537 99,588
Other income (expense):
Interest income 4,457 6,128
Interest expense (27,815) (25,358)

Other income, net 7,942 15,854

Total other income (expense) (3,376) (15,416)
Income before provision for income taxes 96,212 173,121
Provision for income taxes 28,810 1,263
Net income 144,311 94,949
Net (loss) attributable to non-controlling interest (1,089) Net income attributable to the owners of QIAGEN N. V. 96,038 144,311
Weighted average number of diluted common shares 239,064 240,483
Diluted net income per common share attributable to the owners of
QIAGEN N. V. $ 0.40 $ 0.60
Diluted net income per common share attributable to the owners of
QIAGEN N. V. (adjusted) $ 0.98 $ 0.93
ended December 31,
QIAGEN N.V.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
Twelve months

(In $ thousands, except par value) December 31, December 31,

2011 2010
Assets (unaudited)
Current Assets:
Cash and cash equivalents 221,133 828,407
Short-term investments 54,577 106,077
Accounts receivable, net 230,770 197,418
Income taxes receivable 19,009 10,920
Inventories, net 132,236 126,633
Prepaid expenses and other 59,055 64,402
Deferred income taxes 31,652 30,731
Total current assets 748,432 1,364,588
Long-Term Assets:

Property, plant and equipment, net 371,792 345,664

Goodwill 1,733,722 1,352,281
Intangible assets, net 819,487 753,327
Deferred income taxes 26,866 37,182
Other assets 56,154 60,953
Total long-term assets 3,008,021 2,549,407
Total assets 3,756,453 3,913,995
Liabilities and Equity
Current Liabilities:
Short-term loans 142,329 Accounts payable 59,848 47,803
Accrued and other liabilities 213,769 209,054
Income taxes payable 31,211 25,211
Current portion of long-term debt 1,617 75,835
Deferred income taxes 32,883 30,504
Total current liabilities 481,657 388,407
Long-Term Liabilities:

Long-term debt, net of current portion 446,005 797,171

Deferred income taxes 207,112 200,667
Other liabilities 63,881 51,397
Total long-term liabilities 716,998 1,049,235
Equity: